Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Carlton Med ProdfiledCriticalCarlton Med Prod
Publication of PT76274ApublicationCriticalpatent/PT76274A/en
Preparation Of Compounds By Using Micro-Organisms
(AREA)
Abstract
(A) Antigen (I) derived from malignant cells and having (1) molecular mass of 340000-400000, (2) the ability to bind to lectin wheat germ agglutinin, (3) resistance to being boiled and (4) resistance to destruction and to extn. from malignant cells with EtOH, MeOH, xylol or CHCl3-MeOH is new. Pref. (I) is destructable on digestion with pronase; it has a molecular mass component of 350000-490000, a glycoprotein structure with a high carbohydrate content and an isoelectric point of 6.8-7. (B) Monoclonal antibody directed at human tumour cells and recognising and binding with (I) is new. (C) Prodn. of immunogens comprises prepn. of an extract from a cultured cell line derived from human cancer cells, contact of the extract with lectin wheat germ agglutinin for binding of the immunogens to it, elution of non-bonded material and stripping of the immunogens from the agglutinin. (D) Cell culture medium for use in the prepn. of a monoclonal antibody and deposited as CNCM No. 1-195 is new. The (I) is present in the cell membrane of malignant cancer cells and it is obtd. from them by extn. etc. (I) is determined in a tissue specimen by use of an antibody, esp. a monoclonal antibody, in locating malignant tumours in clinical diagnosis.
PT7627483A1982-02-221983-02-22Antibodies and antigens useful in the diagnosis and treatment of cancer
PT76274A
(en)